long intergenic non-protein coding RNA 2802Genealiases: []
Q-omics provides the consensus-scored LINC02802 profile across patient tissues and cancer cell-line models. LINC02802 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC02802 is differentially expressed in 18, with the highest sampling consensus in KIRC. Additionally, LINC02802 RNA expression shows 17,246 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where LINC02802 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02802 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02802 survival associations across molecular data types. LINC02802 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02802 RNA expression–survival associations across cancer types. High LINC02802 expression shows unfavorable associations in LUAD, MESO, KIRP, ACC, LUSC and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC02802 RNA expression.
This table summarizes LINC02802 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02802. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02802 shows lower tumor expression in UCEC and BRCA and higher tumor expression in KIRC, HNSC, KIRP and LIHC. The KIRC box plot shows higher LINC02802 RNA expression in tumor versus normal tissue (log2 FC = +1.555, t-test p < 0.001).
This table shows molecular features associated with LINC02802 in patient tissues and cancer cell lines. In patient samples, LINC02802 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
